Form 4 for MBX MBX Biosciences, Inc.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-03 · accession 0000950170-25-014494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-02-05 | 2025-02-04 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $10.69 | +50.0K | 448.3K | +13% | +$534.5K |
| D | 2025-02-05 | 2025-02-03 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | A - Grant | $0.00 | +243.0K | 243.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-04 | P | A | 50,000 | $10.69 | 448,277 | I By Trust | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.60 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F2) Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | A | A | 243,000 | $0.00 | 243,000 | D | $10.49 · — to 2035-02-03 | 243,000 Common Stock | (F3) 25% of the shares underlying this option vest and become exercisable on February 3, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on such vesting date. |